カテゴリ： GlobalData, アメリカ, 企業調査

Five Prime Therapeutics Inc (FPRX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Five Prime Therapeutics Inc (FPRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9788
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：89
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Five Prime Therapeutics Inc (Five Prime) is a clinical state biopharmaceutical company focusing on the research and development of novel treatments for cancer and inflammatory disorders. The company’s developmental pipeline is based on the discovery platform and library of therapeutic proteins. The company’s pipeline products include cabiralizumab,; FPA144; FPT-155; FPA-150; FPA-151; Tim- 3 antibody; novel I-O biologics and I-O antibody for treating various forms of cancer. Five Prime has also developed proprietary protein screening technologies and rapid in vivo protein production system to identify new targets for protein therapeutics. The company has development collaborations with companies such as Bristol-Myers Squibb, GlaxoSmithKline, Zai Lab, Galaxy Biotech, BioWa-Lonza and UCB Pharma. Five Prime is headquartered in South San Francisco, California, the US.

Five Prime Therapeutics Inc (FPRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Five Prime Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Five Prime Therapeutics Raises US$10 Million In Venture Financing 13
Partnerships 14
Five Prime Therapeutics Enters into Partnership with Roche 14
Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 15
Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 16
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 17
Five Prime Therapeutics Enters Into Research Agreement With Adimab 20
UCB Enters Into Research Agreement With Five Prime Therapeutics 21
Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 22
Licensing Agreements 23
UCB Enters into Licensing Agreement with Five Prime Therapeutics 23
Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24
Ablexis Enters into Licensing Agreement with Five Prime Therapeutics 25
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 26
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 27
Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 28
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 30
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 32
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 33
Equity Offering 35
Five Prime Therapeutics Plans to Raise up to USD250 Million in Public Offering of Shares 35
Five Prime Therapeutics Raises USD115 Million in Public offering of Shares 36
Five Prime Therapeutics Raises USD84.3 Million in Public Offering of Shares 38
Five Prime Therapeutics Completes Private Placement Of Shares For US$21 Million 40
Five Prime Therapeutics Completes Public Offering Of Shares For US$43 Million 41
Five Prime Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option Of IPO For US$71.8 Million 43
Five Prime Therapeutics Inc – Key Competitors 45
Five Prime Therapeutics Inc – Key Employees 46
Five Prime Therapeutics Inc – Locations And Subsidiaries 47
Head Office 47
Recent Developments 48
Financial Announcements 48
Nov 07, 2018: Five Prime Therapeutics announces third quarter 2018 financial results 48
Aug 08, 2018: Five Prime Therapeutics announces second quarter 2018 financial results 51
May 08, 2018: Five Prime Therapeutics Reports First Quarter 2018 Financial Results 53
Feb 27, 2018: Five Prime Announces Fourth Quarter and Full Year 2017 Financial Results 55
Nov 06, 2017: Five Prime Announces Third Quarter 2017 Results and Provides Business Update 59
Aug 08, 2017: Five Prime Announces Second Quarter 2017 Results and Provides Business Update 61
May 04, 2017: Five Prime Announces First Quarter 2017 Results and Provides Business Update 65
Feb 23, 2017: Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results 69
Corporate Communications 72
Nov 05, 2018: Five Prime Therapeutics announces David V. Smith Will Join as Chief Financial Officer 72
May 15, 2018: Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer 73
Mar 13, 2018: Five Prime Therapeutics Announces Executive Change 74
Oct 23, 2017: Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018 75
Aug 17, 2017: Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research 76
Jun 21, 2017: Five Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018 77
May 15, 2017: Five Prime Welcomes Garry Nicholson to Board of Directors 78
Mar 20, 2017: Five Prime Therapeutics Announces Executive Changes 79
Product News 80
04/20/2017: Five Prime to Present Clinical Data on FPA144 at 2017 ASCO Annual Meeting 80
Clinical Trials 81
Jan 02, 2018: Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer 81
Nov 10, 2017: Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting 82
Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155 83
Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 84
Jul 17, 2017: Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development 85
Jun 03, 2017: Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting 86
Other Significant Developments 88
May 29, 2018: Five Prime Therapeutics Walks to End Pancreatic Cancer at PurpleStride San Francisco 2018 88
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89

List of Tables
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Five Prime Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Five Prime Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Five Prime Therapeutics Raises US$10 Million In Venture Financing 13
Five Prime Therapeutics Enters into Partnership with Roche 14
Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 15
Vaccinex Enters into Drug Discovery Agreement with Five Prime Therapeutics 16
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 17
Five Prime Therapeutics Enters Into Research Agreement With Adimab 20
UCB Enters Into Research Agreement With Five Prime Therapeutics 21
Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 22
UCB Enters into Licensing Agreement with Five Prime Therapeutics 23
Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24
Ablexis Enters into Licensing Agreement with Five Prime Therapeutics 25
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 26
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 27
Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 28
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 30
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 32
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 33
Five Prime Therapeutics Plans to Raise up to USD250 Million in Public Offering of Shares 35
Five Prime Therapeutics Raises USD115 Million in Public offering of Shares 36
Five Prime Therapeutics Raises USD84.3 Million in Public Offering of Shares 38
Five Prime Therapeutics Completes Private Placement Of Shares For US$21 Million 40
Five Prime Therapeutics Completes Public Offering Of Shares For US$43 Million 41
Five Prime Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option Of IPO For US$71.8 Million 43
Five Prime Therapeutics Inc, Key Competitors 45
Five Prime Therapeutics Inc, Key Employees 46

List of Figures
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Five Prime Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Five Prime Therapeutics Inc (FPRX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • HSBC Seguros de Vida Argentina S.A.：企業の戦略・SWOT・財務情報
    HSBC Seguros de Vida Argentina S.A. - Strategy, SWOT and Corporate Finance Report Summary HSBC Seguros de Vida Argentina S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Insulet Corp (PODD)：企業の財務・戦略的SWOT分析
    Insulet Corp (PODD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Universal Music Group：企業の戦略的SWOT分析
    Universal Music Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Temple University-製薬・医療分野：企業M&A・提携分析
    Summary Temple University (Temple) is an educational and research university that offers undergraduate and graduate courses. The university offers undergraduate courses in various fields which include arts, media and communication, medicine, engineering, pharmacy and others. Temple offers its degree …
  • Therapix Biosciences Ltd (TRPX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapix’s major product candidates include THX-110, for the trea …
  • Fubon Insurance Co., Ltd.：企業の戦略的SWOT分析
    Fubon Insurance Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • ThermoGenesis Holdings Inc (THMO)：企業の財務・戦略的SWOT分析
    ThermoGenesis Holdings Inc (THMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Ontario Teachers’ Pension Plan：企業のM&A・事業提携・投資動向
    Ontario Teachers' Pension Plan - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ontario Teachers' Pension Plan Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • CIRCOR International Inc (CIR)：石油・ガス：M&Aディール及び事業提携情報
    Summary CIRCOR International Inc (CIRCOR) is an industrial equipment company that designs, manufactures, and markets flow control solutions and engineered products and sub-systems. Its product offerings include integrated flow control solutions, high pressure pneumatic systems, valves, actuation, sw …
  • Evolution Petroleum Corp (EPM)：企業の財務・戦略的SWOT分析
    Summary Evolution Petroleum Corp (EPC), a subsidiary of Esrey Resources Ltd, is an oil and gas company that acquires and explores crude oil and natural gas properties. The company explores for oil, liquefied gas, natural gas, and gas reserves in Delhi field CO2-EOR project. It offers GARP or gas ass …
  • New World Development Co Ltd (17)：企業の財務・戦略的SWOT分析
    New World Development Co Ltd (17) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • City of Hope-製薬・医療分野：企業M&A・提携分析
    Summary City of Hope (COH) is a biomedical research organization that offers cancers, diabetes and infectious diseases treatment services. The organization offers services in the fields of anesthesiology, interventional radiology, surgery, donor matching and marrow transplants, rehabilitation servic …
  • The TJX Companies, Inc.：企業の戦略・SWOT・財務情報
    The TJX Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The TJX Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Cook Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Cook Medical Inc (Cook Medical), that designs, develops and markets medical devices, biological materials and cellular therapies for healthcare market. The company offers products in the fields of critical care medicine, endoscopy, interventional radiology, urology, aortic intervention, lead …
  • Magellan Health Inc (MGLN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Magellan Health Inc (Magellan) is a health care management company which manages behavioral health, radiology and specialty pharmaceuticals, and public sector pharmacy benefits programs. The company provides behavioral healthcare, specialty solutions, and pharmacy management services and int …
  • Telephonics Corp：企業の戦略的SWOT分析
    Telephonics Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Broadcom Inc：企業の戦略・SWOT・財務情報
    Broadcom Inc - Strategy, SWOT and Corporate Finance Report Summary Broadcom Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Spectrum Brands Holdings, Inc.：企業の戦略・SWOT・財務分析
    Spectrum Brands Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Spectrum Brands Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Brazos Electric Cooperative, Inc.：企業の戦略的SWOT分析
    Brazos Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • UbiQ Bio BV-製薬・医療分野：企業M&A・提携分析
    Summary UbiQ Bio BV (UbiQ) is a biotechnology company that develops and commercializes ubiquitinated peptides and assays that enables drug discovery in Ubiquitin field. The company provides products such as ubiquitin-proteasome system, high throughput screening assay reagents and ubiquitinated polyp …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆